Our news

Message from the PAC chair - Dr. Olivier Arnaud

06. April

Quite a strange period in our lives, not only from a personal point of view, but also worldwide, which leads us all to think about what is important. More than ever healthy people realize the risks and wonder what they need to do to keep themselves and their families safe. People with type 1 diabetes (T1D) are used to manage risky situations, every day of their life. And therefore maybe more prepared to act and react than others. However, this COVID-19 virus is stressful because of our lack of knowledge and the potential higher risk of complication when you are a person with T1D.
INNODIA remains active, also during the ongoing pandemic. Now more than ever, the work of our basic and clinical researchers is crucial to decrease the burden of this disease.

It is time to make more politicians, funders, even scientists aware of the importance of investing in research for T1D. INNODIA is the unique European platform which is designed to accelerate the development of future key drugs for curing type 1 diabetes.
We will overcome this worrying COVID-19 pandemic! Once the situation is more controlled, INNODIA will be ready to speed up the extremely valuable work they do. Our researchers, clinicians, companies and organizational people keep the logistics running and move ahead with integration and analysis of already available data sets. We will be back on track after the COVID-19 pandemic and specifically ready to start the planned clinical trials.

Be safe, stay at home, which is certainly advised in all countries. Keep in contact with us and remain assured that the Patient Advisory Committee watch over this great INNODIA project. We will make sure that science continues to advance towards a cure for Type 1 Diabetes.
THANKS a lot.